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Abstract
This chapter provides a summary of the aetiology, diagnosis, investigation and man-
agement of anal fissure. It gives an overview of clinical anatomy and pathophysiology 
related to anal fissure. Focusing on anal sphincter hypertonia as the key factor for anal 
fissure progression, the chapter draws attention to perpetuating factors that contribute 
to a vicious cycle of fissure non-healing and addresses management options for these 
factors. This chapter also looks at the way how different treatment options for anal fis-
sure emerged over time and uses evidence-based medicine to compare these options. 
“Fissure-in-ANO” concludes with summarising the treatment options and suggesting an 
algorithm for management of acute and chronic anal fissures.
Keywords: anal fissure, sphincter hypertonia, lateral internal sphincterotomy, glyceryl 
trinitrate, faecal incontinence
1. Introduction
Anal fissure, also known as fissure-in-ano, is a common cause of perianal pain. Patients often 
describe the pain they experience during a bowel movement as ‘passing shards of glass’, and 
the pain is often associated with rectal bleeding.
An anal fissure is an ulcer like longitudinal tear in the squamous epithelium of the anal canal, 
which extends from the anal verge cephalad sometimes up to the level of the dentate line. It 
usually causes pain both during and for 1–2 h after defecation [1]. This feature helps to distin-
guish anal fissure from other causes of anal pain such as perianal and ischiorectal abscesses, 
thrombosed haemorrhoids, viral ulcers, and others. As patients may be embarrassed about 
the anatomic location of their symptoms, they may present to care late in the course of their 
illness.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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An annual incidence of 1.1 per 1000 person-years is reported, equivalent to an average life-
time risk of 7.8%. There are approximately 342,000 new cases diagnosed in the United States 
of America annually, a figure similar to appendectomies performed, but study estimates vary 
widely. One retrospective population-based study found that anal fissures most commonly 
affected females aged 12–24 years and males 55–64 years of age [2]. Risk factors included 
chronic constipation, obesity, hypothyroidism, and solid tumours.
2. Anatomy
An acute anal fissure has the appearance of a clean longitudinal tear in the anoderm, some-
times with surrounding inflammation. A chronic fissure is usually deeper and generally has 
exposed internal anal sphincter (IAS) fibres at its base. It is frequently associated with a hyper-
trophic anal papilla at its proximal aspect and with an irritated skin tag or sentinel pile at its 
distal aspect.
The anal canal can be described in terms of the ‘surgical’ and ‘anatomical’ anal canal. The 
surgical anal canal is approximately 4 cm long extending from the anal verge (anocutane-
ous line) to the anorectal ring (muscular ring formed at the junction of the rectum and anal 
canal) proximally. The anatomical anal canal is approximately 2 cm in length and extends 
from the anal verge distally to the dentate line (junction of the ectoderm and endoderm in 
the anal canal) proximally.
The epithelium of the anal canal between the anal verge below and the pectinate line above is 
anal mucosa. This area has somatic sensation and is the reason why anal fissures are painful. 
The anal canal just above the pectinate line for about 1–2 cm is called the anal transitional zone 
(ATZ). Above the ATZ, the anal canal is lined with columnar epithelium.
Figure 1. Schematic representation of anal canal anatomy.
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The inner smooth muscle layer of the colon and rectum thickens in its lowermost part over 
a length of 2.5–4 cm of the rectum to form the IAS. The IAS is an involuntary muscle that is 
in a state of continuous contraction to prevent flatal and faecal incontinence. The external 
anal sphincter (EAS) forms a circular tube around the anal canal. It merges proximally with 
the puborectalis and the levator ani muscles to form a single complex. It is supplied by the 
inferior rectal nerves and by a perineal branch of the fourth sacral nerve. This muscle is pre-
dominantly under voluntary contraction.
An anal fissure involves only the epithelium and when chronic in nature it involves the full 
thickness of the anal mucosa rendering fibres of the IAS visible. Hypertonia and hypertrophy 
of the IAS are commonly observed (Figures 1–3).
Figure 2. Schematic description of anal fissure.
Figure 3. Posterior fissure-in-ano.
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3. Pathophysiology
Different factors are involved in initiating and perpetuating the symptoms of an anal fissure. 
Stretching of the anal mucosa beyond its physiological limits initiates the cycle, which causes 
a breakdown in mucosal integrity in areas with poor muscular support i.e. an area of the 
relative paucity of support between the coccyx and the anorectal ring. This is followed by 
attempts at healing that are compromised by bowel movements that bring about repeated 
injury due to stretching of the whole muscular complex. The impaired healing and pain leads 
to persistent spasm of the IAS and an increased mean average resting luminal pressure. The 
persistent spasm prevents opposition of the tear leading to impaired wound healing, bacterial 
colonisation and progression from an acute to a chronic anal fissure in up to 40% of patients 
[3]. The high anal resting tone also reduces the blood supply to the posterior midline, an 
area of poor vascular supply of the anal canal. This explains why approximately 90% of anal 
fissures in both men and women are located posteriorly in the midline. Another contribut-
ing factor for posterior anal fissure is lack of clinical perineal descent in people with anal 
fissure which leads to repeated preferential over-stretching of the posterior anal sphincter 
complex and perineum. On the contrary, normally during defecation the anal sphincters and 
the puborectalis muscle relax, which allows the anorectal angle to widen and the perineum to 
descend avoiding overstretching of the posterior perineum [4].
Anterior fissures occur in 10% of patients, more commonly women and predominantly after 
vaginal delivery. Atypical fissures are very rare (less than 1%) and are usually found away 
from the midline or are multiple in number and should raise a suspicion of underlying condi-
tions such as inflammatory bowel disease e.g. Crohn’s disease, sexually transmitted diseases 
(human immunodeficiency disease, syphilis, or herpes), anal cancer or tuberculosis [5].
Studies have shown that people with anal fissures have increased tone [6] and hypertrophy 
of the IAS. The anal spasm can additionally cause ischemia of sensitive rectal tissue, which 
exacerbates the condition [7]. This concept is utilised in both the medical and surgical man-
agement of anal fissure.
Anal hypertonicity may aggravate perfusion to the anal canal. Studies using anorectal 
manometry have demonstrated hypertonia of the IAS and have shown fewer IAS relaxations 
in patients with chronic anal fissures [8]. Relative ischemia of the posterior anal canal has been 
demonstrated in chronic, non-healing anal fissures. Post-mortem studies have shown that the 
posterior midline of the anal canal is poorly perfused in 85% of patients. Increased IAS tone 
can compromise perfusion to the posterior commissure, as it increases pressure on vessels 
passing in a perpendicular direction through the sphincter where blood flow is already sparse 
[9]. Doppler laser flow studies have clearly shown lower anodermal blood flow at the fissure 
site compared with the posterior commissure of controls [8, 10]. Nitrous oxide synthase was 
also found to be intrinsically lower in individuals with fissures in one study [11].
4. Clinical findings
Patients can present with an acute or a chronic fissure-in-ano. In the acute setting, patients 
often complain of severe rectal pain, especially with bowel movements, described as intense 
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and sharp and “like passing shards of glass or razor blades.” The pain eases until the next 
bowel movement. The severity of the pain can be likened to that of urolithiasis or child-
birth for some, while for others the symptoms are mild and patients need reassurance only. 
Patients with a chronic anal fissure complain of constant pain because of sphincter hyper-
trophy and spasm, with exacerbation of the pain during defecation. Passage of fresh bright 
red blood is less common as the initial presenting symptom. Patients are usually constipated 
and have a straining pattern of defecation. Painful defecation leads to avoidance of defeca-
tion and results in a vicious, self-perpetuating cycle. They tend to eat less to avoid the need 
for passing stool. Some patients report episodes of diarrhoea prior to the commencement of 
symptoms. Other patients complain of pruritus ani also, albeit this is not a common present-
ing symptom for a fissure. On history taking, the patient may point towards the passing of 
a large or hard stool as the initiating event. Anal intercourse and penetration with foreign 
bodies must also be enquired about, as should a personal or family history of inflammatory 
bowel disease.
5. Investigations
Physical examination in the left lateral position by gently separating the buttocks, and evert-
ing the anal verge usually exposes linear separation of the anoderm at the lower half of the 
anal canal. Severe pain can be induced with digital rectal or proctoscopic examination, so 
should not be attempted if a fissure is expected or demonstrable in the awake setting. If sus-
pecting a secondary pathology and proctoscopy and digital examination are necessary, this 
should be done under local, regional or general anaesthesia.
If the diagnosis is unclear and the clinician is unable to see the fissure at the bedside, or a 
patient who is high risk for colorectal cancer and presents with significant fresh bleeding 
per rectum, examination under anaesthesia (EUA) with anoscopy, colonoscopy and tissue 
sampling may be warranted. Similarly, dependent on findings at EUA, further investigation 
with endoanal ultrasound, CT and MRI scanning may be required.
6. Differential diagnosis
Other conditions that can present with perianal pain and bleeding PR include thrombosed 
haemorrhoid, anal fistula, solitary rectal ulcer, Crohn’s disease, malignancy or tuberculosis. 
These can be excluded by history and careful clinical assessment.
7. Classification
Anal fissures are classified on the basis of chronicity and morphological appearance. Acute fis-
sures are defined as those with duration of symptoms of 6 weeks or less. They usually involve 
only the superficial mucosal layer and the base of the fissure does not have visible IAS fibres. 
They tend to have sharply demarcated, fresh mucosal edges, often with granulation tissue at 
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the base [12] and often they will heal spontaneously. Lindsey et al. proposed a definition for 
chronic anal fissure as ‘the presence of visible transverse IAS fibres at the base of an anal fissure 
of duration not less than 6 weeks’ [13]. Over time, the IAS hypertrophies and becomes more 
effective in keeping the wound open and thus, prevents spontaneous wound healing. Chronic 
anal fissures have distinct anatomical features, such as the aforementioned visible sphincter 
fibres at the fissure base along with an anal papilla, sentinel pile and indurated margins.
8. Treatment options
Any treatment plan needs to address the following issues: (1) supportive measures, (2) atrau-
matic passage of stool, (3) pain management, (4) abnormal pattern of defecation, e.g. exces-
sive straining, and (5) decreasing anal sphincter tone and local ischemia in patients with a 
hypertonic sphincter.
8.1. Supportive measures
The American Society of Colorectal Surgeons (ASCRS) recommends non-operative manage-
ment as the initial treatment. ASCRS suggests that nearly 50% patients can achieve symptom 
resolution with the use of supportive measures such as sitz baths, bulking agents and topical 
anaesthetics and steroids [14–19]. A sitz bath comprises immersing the anus in lukewarm 
water for 10–15 min, two to three times a day. The treatment supplemented with a sitz bath 
regimen is associated with improved pain relief [15]. Maintenance therapy with fibre is asso-
ciated with lower rates of fissure recurrence compared with placebo [18].
8.2. Atraumatic passage of stool
Constipation leads to straining and in turn usually worsening of the fissure symptoms. 
Laxatives, stool softeners and appropriate intake of dietary fibre are advised by ASCRS. The 
treatment of acute anal fissure with fibre supplementation has been associated with increased 
healing rates, improvement of symptoms, and prevention of recurrence [15, 18]. Fibre works 
by absorbing water, forming a viscus and bulky stool that promotes peristalsis and renders 
the stool easier to evacuate and in turn reduces the need for straining during defaecation. 
Stool softeners work by increasing the water content of stool and thus avoiding trauma to the 
anal canal lining during defecation. Mineral oil also aids to facilitate passage of stool without 
much stretching or abrasion of the anal mucosa, but it is not recommended for indefinite use.
8.3. Pain management
Topical anaesthetics in combination with sitz baths and the other above mentioned support-
ing strategies provide good pain control. Analgesics are often required for patient comfort. 
Non-steroidal anti-inflammatory drugs, paracetamol, and on occasion opioid analgesics are 
required, the latter requiring concurrent laxative use to avoid further constipation.
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8.4. Abnormal pattern of defecation
Assessment of dyssynergic defaecation and anorectal feedback may be required in patients 
with excessive straining at defecation. A manual perineum support has been shown to help 
in patients with defecatory issues [20]. A novel posterior perineal device incorporated in the 
toilet seat has also shown improvement in pain, constipation and bleeding symptoms [21].
8.5. Decreasing sphincter tone and local ischaemia
Pharmacological and surgical options are available to manage increased IAS tone with associ-
ated local ischaemia. For chronic fissures, studies have suggested lateral internal sphincterot-
omy (LIS) has better results as compared to pharmacological agents [22]. ASCRS recommends 
LIS as the first line of treatment in the selected group of patients with no underlying faecal 
incontinence of any degree. The available options are discussed below.
8.5.1. Pharmacological management
Calcium channel blockers and nitrates are the most commonly used pharmacological agents. 
Both topical and oral forms are in use. Patients with an acute fissure can be treated with 
supportive measures only, but the NICE (National Institute for Health and Care Excellence) 
guidelines recommend using nitrates as an adjunct for 6–8 weeks followed by a re-evaluation 
and prescribing another course of medication if required. While for Diltiazem, NICE recom-
mends usage only on specialist advised for those who cannot use GTN, as it’s an unlicensed 
product. If symptoms persist then EUA and further investigation is needed.
Medical management has a much-reduced incidence of the dreaded complication of fae-
cal incontinence but has a higher recurrence rate (around 50% for medical management as 
compared to 3–6% for LIS) [23–25]. This recurrence rate is similar for both calcium channel 
blockers and nitrates. However, patients who are already on these drugs for hypertension and 
ischemic heart disease may not be suitable candidates as the systemic therapy did not prevent 
the development of the fissure and thus may not aid in its healing.
Medical management does not provide a solution for skin tags, sentinel piles and fibrous 
polyps. These persist even after symptoms have resolved and can themselves cause bleeding 
or pain with trauma or can be a cause of faecal soilage.
8.5.1.1. Calcium channel blockers
Calcium channel blockers reduce anal tone and spontaneous activity of the sphincter by 
decreasing the intracellular availability of calcium. This is done by blocking the L-type cal-
cium channels involved in the maintenance of IAS tone [26–28]. ASCRS recommends using 
calcium channel blockers as opposed to topical nitrates because of the superior side effect 
profile while having similar efficacy. In a recent systematic review and meta-analysis, topical 
calcium channel blockers were found to have better healing rates (21.3 vs. 38.4% unhealed 
fissures) as compared to oral, with fewer side effects [29].
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8.5.1.1.1. Nifedipine
Studies have shown that nifedipine has a local anti-inflammatory effect [30] and produces 
modulating effects on the microcirculation [31]. In a trial comparing nifedipine and nitro-
glycerin as the treatment option, nifedipine proved to be better in healing (89 vs. 58%) and 
also had fewer side effects, while recurrence was frequent with both (42% with nifedipine vs. 
31% with GTN) [32]. Direct comparison of oral and topical nifedipine found similar rates of 
healing and pain relief [27]. Given the higher incidence of systemic effects associated with oral 
calcium channel blockers, topical delivery is preferred.
8.5.1.1.2. Diltiazem
Recurrence is a problem for this class of drug. In one of the few long-term trials [33], more than 
60% of patients experienced a recurrence within 2 years after cessation of therapy. One study 
reported that topical diltiazem has superior healing rates to oral diltiazem (65 vs. 38%) [34]. 
The main side effects include migraine and pruritus ani in 10% of patients [35, 36].
8.5.1.2. Nitrates
Myenteric nerves innervating the internal sphincter muscle of the anus produce and release 
nitric oxide, the chemical messenger that mediates relaxation of this muscle. Nitroglycerin, 
which is locally metabolised to nitric oxide, lowers the mean resting pressure of the anal 
sphincter when applied topically to the anus.
8.5.1.2.1. Nitroglycerin
Nitroglycerin promotes healing by decreasing pressure in the anal sphincter and concur-
rently increasing blood flow. For an acute fissure, NICE guidelines recommend 0.4% GTN 
as a second line treatment option if only supportive measures are not effective after 1 week 
of treatment, as a proportion of acute anal fissures heal spontaneously within 2 weeks. For 
chronic fissures, intra-anal application of GTN (also called glyceryl trinitrate, GTN) oint-
ment directly to the IAS helps in fissure healing in approximately 50% [37]. Commonly used 
preparations come in either 0.2 or 0.4% strengths. Different doses ranging from 0.05 to 0.4% 
have been studied and the dose has not been shown to effect healing in three studies which 
compared different doses [38–40].
Headache is the main side effect occurring in at least 30% of treated patients [37]. Typically, these 
headaches last for no more than 30 min and occur 10–15 min after application. Hypotension 
is another side effect, brought about by vasodilation. It causes dizziness and thus, susceptible 
patients should lie down after application of the ointment to avoid dizziness. Topical GTN 
should be avoided within 24 h of taking erectile dysfunction medications such as Sildenafil.
A large Cochrane review compared the efficacy of 17 different therapies and concluded that 
topical GTN is better than placebo for anal fissures and is equivalent to botulinum toxin (BTA) 
injection and topical calcium channel blockers. GTN tends to cause more side effects, specifi-
cally headache [23].
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8.5.1.3. Other medications and treatment options
Parasympathomimetic medications such as Bethanechol and Indoramin (alpha blocker), beta 
agonists like Salbutamol, natural products like Myoxinol ointment [41], egg yolks [42], and 
injection of sclerosing agents [43] have been tried with varying results.
Use of percutaneous posterior tibial nerve stimulation has also been suggested as a safe and 
effective alternative [44–46]. Studies have shown it to be some ways superior to GTN ointment 
for the treatment of chronic anal fissure. In a prospective randomised study of 40 patients who 
had persistent anal fissures despite 6 weeks of supportive measures, patients were randomised to 
either perianal application of GTN ointment (twice daily for 8 weeks) or percutaneous posterior 
tibial nerve stimulation (30–min session 2 days per week for 8 weeks). After 8 weeks of treatment, 
the healing rate in the percutaneous posterior tibial nerve stimulation group was 87.5 vs. 65.0% 
in the GTN ointment group. There were no side effects or treatment withdrawal in the nerve 
stimulation group as compared to 15% withdrawal in the GTN group due to headache [44].
8.5.1.4. Botulinum toxin A
The British Medical Journal (BMJ) best practice recommends using botulinum toxin (BTA) if topi-
cal agents are unsuccessful. BTA is used for performing a chemical sphincterotomy. The major 
effect of BTA on the IAS is blockade of sympathetic (noradrenaline mediated) neural output. 
This is probably a postganglionic action, involving a reduction in noradrenaline release at the 
neuromuscular junction causing short-term paralysis of the IAS, resulting in a reduction in anal 
tone [47, 48]. It can be used to treat acute and chronic anal fissures. The site of injection is still not 
clear and different sites have been tried (directly under the fissure or in both sides of the fissure 
or circumferential injections). There is no dosage or injection site with evidence of superiority. A 
meta-analysis shows there is no dose-dependent efficiency. The postoperative incontinence rate 
is not related to the dosage regardless of the type of formulation of BTA used. Also, there is no 
difference in healing rates with regard to the site and number of injections per session [49]. BTA 
has been shown to give comparable results with internal vs. external anal sphincter injection. 
One explanation of this is possible diffusion of the toxin from EAS to IAS [50, 51]. A second injec-
tion for an unsatisfactory response to the initial injection has shown good results where healing 
rates are around 60–95% after the second session of injections, with recurrence rates of 12.5% 
at 6 months and with no reports of anaphylaxis [23, 52, 53]. The effect is thought to last about 
3 months until nerve endings regenerate allowing acute fissures (and sometimes chronic fis-
sures) to heal and symptoms to resolve [54]. The incidence of postoperative incontinence (5–10%) 
[23, 49] (both faecal and flatal) needs to be considered and patients counselled regarding same.
In an updated systematic review and meta-analysis of randomised controlled trials, BTA was 
associated with fewer side effects than GTN but there was no difference in fissure healing 
or recurrence, although there was an increased incidence of transient anal incontinence [55]. 
Haematomas and subcutaneous infections are other commonly reported but infrequent side 
effects. A double-blind randomised controlled trial that compared topical diltiazem with BTA 
demonstrated that BTA has better healing rates in the short term but after 3 months diltiazem 
and BTA resulted in similar healing rates. Also, no significant difference in pain reduction was 
observed between the treatments [54]. ASCRS reports that BTA has similar results compared 
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with topical therapies as first-line therapy for chronic anal fissures, and modest improvement 
in healing rates as second-line therapy following treatment [56].
8.5.1.5. Summation of pharmacological management
The Association of Coloproctology of Great Britain and Ireland (ACPGBI) recommends sup-
portive treatment for both acute and chronic anal fissures, in combination with a calcium chan-
nel blocker for 6–8 weeks. If resistant to treatment, they recommend the injection of 20–25 units 
of BTA [57]. ASCRS recommends non-operative treatment of acute anal fissures e.g., sitz baths, 
psyllium fibre and bulking agents as the first step in therapy. Almost half of all patients who 
have an acute anal fissure will experience symptom resolution with non-operative measures [14, 
15]. If symptoms persist, then pharmacological and/or surgical options should be considered.
8.5.2. Surgical options
As per a recent systematic review and meta-analysis of 148 trials, surgical intervention is 
significantly more effective for chronic anal fissure than medical management [24] but car-
ries the additional potential risk of incontinence. The main contraindication to surgery for 
an anal fissure is impaired faecal continence, a condition that might worsen with surgery. 
This contraindication mostly applies to patients with minor incontinence, or who are at risk 
of incontinence due to a weakened sphincter complex, e.g., multiparous women and older 
patients. Surgery is offered to patients in whom an acute fissure is not responding to medical 
treatment and to those patients with chronic fissures [58–61]. No specific preoperative prepa-
ration is needed, intravenous antibiotics are not recommended [62] and preoperative enemas 
can be very painful for the patient and thus should be avoided.
The following are the most commonly performed operations for anal fissures.
8.5.2.1. Sphincterotomy procedures
The aim of a sphincterotomy is to release tension in the IAS by dividing it and thus allowing heal-
ing [63]. In broad terms, there are two categorised subtypes: the posterior and lateral approaches.
Posterior sphincterotomy is no longer recommended as it potentially leaves a keyhole defect 
[64]. Lateral internal sphincterotomy (LIS) is the gold standard surgical procedure [65]. LIS 
can be performed by either the open or closed technique with similar outcomes [66] and 
healing rates of approximately 95%. The open technique involves making an incision at the 
anoderm to expose the IAS and then a division of the IAS under direct vision. For the closed 
technique, a scalpel blade is inserted directly under the anoderm or into the intersphincteric 
groove and the sphincter is divided without widely incising the anal mucosa.
Common complications include recurrence in up to 6% and incontinence of flatus or stool 
(usually transient) in 3.4–4.4% of patients [24]. This procedure commonly involves division 
of the IAS from its distal end to the level of dentate line or just proximal to it. LIS has been 
shown to result in better quality of life than that following medical therapy. Importantly, 
LIS also negates any patient compliance issues associated with medical therapy. Due to 
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this, LIS can be offered as 1st line treatment for patients with chronic anal fissures and no 
underlying symptoms of or predisposition to incontinence.
A modified form called a tailored sphincterotomy or fissure apex sphincterotomy involves divi-
sion of the IAS up to the level of the apex of the fissure and thus it preserves more sphincteric 
muscle fibres. Two randomised controlled trials have reported a clinically significant reduction 
in incontinence with fissure apex sphincterotomy as compared the aforementioned traditional 
LIS [67, 68]. Another described technique is that of the calibrated sphincterotomy. A prede-
termined anal canal diameter (3 cm) is achieved by transecting the sphincter muscles. Results 
from a randomised controlled trial show equivalent healing in calibrated LIS and fissure apex 
LIS, but the incidence of faecal incontinence was higher in the fissure apex LIS group [69].
A recent review using three-dimensional anal ultrasonography to determine the extent of IAS 
division during LIS in women reported that the safest method is to divide less than 25% of 
the sphincter, which in women corresponds to less than 1 cm. No incontinence was observed 
in these patients [70]. It is important to ensure the sphincter is actually divided during LIS. A 
study by Farouk et al. evaluated patients with persistent fissures post-sphincterotomy with 
ultrasound. Almost 70% had no demonstrable division of the IAS on imaging [71]. If LIS fails, 
endoanal ultrasound should be performed to assess the sphincter (Figure 4).
8.5.2.2. Anal advancement flap
This is a sphincter-saving procedure that has a very low reported incidence of postopera-
tive minor faecal incontinence (0–6%). An anocutaneous (dermal V-Y or house) flap can be 
used for chronic non-healing fissures in patients with an increased risk of developing faecal 
incontinence (e.g. older adults, multiparous women, patients with recurrent fissures). This 
procedure has been shown to have good healing rates (81–100%) [53, 72]. Anal advancement 
flaps have been utilised as a subsequent therapy to LIS or BTA injection resulting in less 
postoperative pain and improved healing [73, 74].
8.5.2.3. Anal dilatation
The concept of sphincter stretching was first described by Recamier in 1838 for the treat-
ment of proctalgia fugax and anal fissure. In 1968, Lord introduced a technique involving 
Figure 4. Diagramatic presentation of Lateral internal shincterotomy.
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the insertion of four fingers of each hand into the anal canal and stretching over the course of 
3–4 min. Nelson suggested abandoning the dilatation procedures by manual stretching [66]. 
This procedure is associated with higher rates of recurrence and incontinence [57].
A Cochrane review was performed of seven randomised controlled trials comparing anal 
stretch with internal sphincterotomy. The results significantly favoured sphincterotomy over 
anal stretch for efficacy (OR = 3.35; 95% CI = 1.55–7.26; here, OR: odds ratio, CI: confidence 
interval) and incontinence to flatus or faeces (OR = 4.03; 95% CI = 2.04–7.46) [23]. With the 
advent of endoanal ultrasound, sphincter defects after anal dilation are now readily detect-
able [75, 76]. In one study, IAS defects were visualised in 65% with 12.5% reporting inconti-
nence. EAS defects were also found in 11/18 patients with incontinence [75].
Pneumatic balloon dilation (PBD) seems to be an effective, safe, easy procedure that decreases 
anal resting pressure without endosonographically detectable significant sphincter damage. 
A randomised controlled trial reported on PBD compared to LIS for the treatment of chronic 
anal fissure. Pneumatic dilation was performed with a 40 mm diameter, 60 mm in length anal 
balloon (Microvasive, Genova, Italy) with the balloon inflated to 20 psi for 6 min. Overall heal-
ing rates at 6 weeks were 83 and 92% for PBD and LIS, respectively. Based on preoperative and 
postoperative manometry, both techniques reduced anal pressures by ~30%. The PBD group 
did demonstrate mild transient faecal incontinence; however, at 24-month follow-up, the inci-
dence of incontinence in the PBD group was 0%, but 16% in the LIS group (p < 0.0001) [77].
8.5.2.4. Fissurectomy
Fissurectomy entails excision of the scarred superficial skin around the anal fissure, chronic 
granulation tissue, hypertrophied papilla and the skin tag or sentinel pile. This then leaves a 
base of healthy tissue that will hopefully heal. The wound is either left open or closed primar-
ily. In one clinical trial by Mousavi et al., fissurectomy was considered inferior to LIS. Another 
study by Barnes et al. reported on a combined modality of fissurectomy with BTA injection 
and had a 93% healing rate with only transient incontinence to flatus in 7% [78]. Fissurectomy 
has also been performed in conjunction with GTN or BTA injection to treat anal fissures with 
no recurrence and no sphincter damage on post operative endosonography [79, 80].
8.5.2.5. Surgical adjuncts
Persistence of hypertrophied papillae, skin tags and polyps often leads to patient dissatisfac-
tion. Removal of hypertrophied anal papillae and fibrous anal polyps should be considered 
as a part of the surgical procedure. A randomised controlled trial found 84% of patients who 
had removal of the polyp, papilla or skin tag were satisfied at 2 years postoperatively as 
compared to only 58% of the control group [81]. A radiofrequency procedure can also useful 
in the eradication of these concomitant pathologies [82].
8.5.2.6. Summation of surgical management
American and British surgical societies recommend against uncontrolled manual dilata-
tion. ASCRS recommend that LIS may be offered as first-line therapy without prior medical 
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treatment to decrease IAS tone in a selected group of patients. The ACPGBI recommends LIS 
in cases of failed medical treatment, or of chronic anal fissures in association with a hypertonic 
anal sphincter. Modifications of the traditional sphincterotomy procedure have shown promis-
ing results. Anal advancement flaps can be an option for high-risk patients with IAS hypotonia.
8.5.3. Combination procedures
Primary wound healing can be achieved by combining anal advancement flap with LIS or 
BTA injection providing faster pain relief and potentially providing better functional results 
[83]. Theodoropoulos et al. found significantly less postoperative pain, faster healing, and 
fewer incontinence episodes in the tailored LIS plus flap group in comparison to the conven-
tional LIS alone group [74]. Magdy et al. found tailored LIS with V-Y flap produced a superior 
healing rate, with relatively lesser complications and less rate of recurrence as compared to 
LIS or anal advancement flap alone [84]. In a randomised controlled trial of 99 patients, the 
combination of diltiazem and BTA injection was found to be as effective as LIS in patients 
with chronic anal fissure of the duration of 1 year or less [85].
9. Overview and comparison of side effects
Different side effects are associated with different therapies. The outcomes and side effects of the 
treatments for anal fissures reported in the literature are inconsistent. The recent systematic review 
and meta-analysis of 148 trials reported that nitrates are associated with headache in 20–30% of 
cases or even higher [24, 38, 86]. Higher doses do not seem to influence efficacy but do increase 
the side effect profile, especially headaches. Oral calcium channel blockers also have a reasonably 
high incidence of associated headache, but in their topical form, this is reduced to only 16%.
Variable incontinence rates have been described. LIS has been shown to have an incontinence 
incidence rate of 3.4–4.4%. BTA injection has a reported incontinence rate of 2.3%, GTN 1.1% 
and topical calcium channel blockers 1.4%. Other side effects include perianal itching and der-
matitis [24]. Medical therapies have been shown to have recurrence rates as high as 50% [25].
Following chart compares different aspects of different treatment options (Figure 5).
Figure 5. Chart comparing different aspects of different treatment options.
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10. Fissures with low anal pressures
The management of anal fissure is mainly based on relieving anal hypertonicity. Patients with 
anterior anal fissures have been shown to have significantly lower anal pressures, suggesting 
a different pathophysiology in the development of these fissures [87, 88]. Low-pressure anal 
fissures are most commonly seen in postpartum patients. These patients are at particularly 
high risk for incontinence with measures directed at reducing anal hypertonia. Thus, it is 
especially important to approach anterior and low-pressure fissures more cautiously. It may 
be beneficial to perform anorectal manometry before proceeding with a treatment algorithm.
Various small studies have shown success with advancement anoplasty, or fissurectomy with 
advancement anoplasty, in patients with low-pressure anal fissures with reported healing 
rates ranging from 87 to 100% [89–91]. Advancement flap surgery may be an acceptable first 
approach to low-pressure fissures.
11. Novel therapies
Autologous adipose tissue injection has been shown to result in healing in 75% of treated 
anal fissures and 80% resolution of anal stenosis in patients with chronic anal fissure who 
failed previous medical and surgical therapy. Surgical treatment consisted of transplant of 
purified autologous fat retrieved from the hypogastrium [92]. Another reported technique is 
laser electrocoagulation of the fissure and its margins, leaving the IAS virtually intact. This 
destroys the scarred tissue and gives the tissue a chance to heal gradually from the bottom to 
the top of the anal ulcer of the fissure. A study reporting on 200 patients found no recurrence 
and no complications on follow-up [93].
A randomised prospective study compared anal self-massage with manual anal dilators and 
found a better resolution of an acute anal fissure in a shorter time. The anal self-massage con-
sisted of the introduction of the patients’ own index finger into the anal canal (with lubricant 
cream) for 10 min twice a day for the first 2 days of treatment. Following this initial 2-day 
strategy, patients were then instructed to perform a circular motion with the finger for 10 min 
twice a day for a further 5 days [94].
12. Treatment algorithm
Comparing the potential risks and benefits of different medical and surgical options as per 
evidence based medicine, the following treatment algorithm is proposed (Figure 6).
The authors favour the above algorithm, as many patients will decline the definitive treat-
ment of surgical sphincterotomy when they are made aware of the small, but potential, com-
plication of incontinence. Thus, commencing with supportive measures is the first step and 
highly unlikely to cause any lasting side effects. BTA injection is not licenced for nor present 
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in formal guidelines, but it is utilised by many surgeons as a bridging step between topical 
therapy and definitive surgery, with the added option of being able to repeat the injection if 
required. It often seems to be a more acceptable option to the patient also, in that it involves 
an injection as opposed to cutting a muscle, one sounding like a far more serious and complex 
operation than the other. In cases of failure of LIS, patients should be assessed with anorectal 
manometry and endoanal ultrasound. If the amount of sphincter divided was inadequate, 
repeat internal sphincterotomy can be done, or contralateral LIS can be performed [95]. 
Patients’ wishes should be taken into consideration for further management.
13. Conclusion
An anal fissure is a painful ulceration predominantly associated with spasm of the 
IAS. Treatment is based on controlling pain, sphincter tone and regularisation of bowel move-
ments. There is no consensus found among different guidelines from including Europe and 
America, regarding a definitive treatment algorithm with variation between health services 
and individual clinicians alike. While acute fissures usually heal with supportive measures 
and topical analgesic agents, some guidelines suggest early use of pharmacological agents 
even in the acute phase, while for chronic fissures medical and surgical treatments both have 
been recommended. Different pharmacological agents have advantages and side effects, but 
lateral internal sphincterotomy or its variants have been found to be best. Novel therapies 
have been tested but need more research. The authors like to take an aptly described ‘bottom 
up’ approach, commencing with supportive measures and topical therapies, followed by BTA 
Figure 6. Algorithm for management of anal fissure.
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injection if the patient wishes and leaving definitive surgery in the form of a sphincterotomy 
or advancement flap as the final treatment option.
Nomenclature
AF Anal fissure
ASCRS American Society of Colorectal Surgeons
LIS Lateral internal sphincterotomy
IAS Internal anal sphincter
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BTA Botulin toxin A
GTN Glyceryl trinitrate
CCBs Calcium channel blockers
PR Per rectal
NICE National Institute for Health and Care Excellence
RCT Randomised control trial
PBD Pneumatic balloon dilatation
BMJ British Medical Journal
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